Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome

Front Pharmacol. 2024 Feb 12:15:1337436. doi: 10.3389/fphar.2024.1337436. eCollection 2024.

Abstract

IC50 = 11 nM (PI3Kδ); 244 nM (PI3Kα); 424 nM (PI3Kβ), 2,230 nM (PI3Kγ).

Keywords: alpelisib; copanlisib; duvelisib; idelalisib; leniolisib; phosphatidylinositol 3-kinase.

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.